New combo therapy targets untreatable liver cancer

NCT ID NCT06040099

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 01, 2026 · Updated 3 times

Summary

This phase 2 trial tests whether giving two immunotherapy drugs (durvalumab and bevacizumab) after a procedure that delivers tiny radioactive beads to the liver can help people with liver cancer that cannot be surgically removed. The study includes 58 participants and measures how long the cancer stays under control and what side effects occur. The approach aims to shrink tumors and delay progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: durvalumab (Imfinzi) and bevacizumab (Avastin) given intravenously, plus yttrium-90 glass microspheres (TheraSphere) delivered via a procedure called transarterial radioembolization
What this could lead to: If this works, it could provide a new treatment option for people with liver cancer that cannot be removed by surgery, potentially slowing the cancer's growth.
What could go wrong: This is a small, early-phase study with only 58 participants and no comparison group, so results may not apply to everyone. The combination of treatments can cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma Liver Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

Research Site

Aurora, Colorado, 80045, United States
Research Site

Gainesville, Florida, 32608, United States
Research Site

Orlando, Florida, 32804, United States
Research Site

Atlanta, Georgia, 30322, United States
Research Site

Atlanta, Georgia, 30342, United States
Research Site

Chicago, Illinois, 60611, United States
Research Site

Boston, Massachusetts, 02118, United States
Research Site

Detroit, Michigan, 48201, United States
Research Site

St Louis, Missouri, 63110, United States
Research Site

Trenton, New Jersey, 08690, United States
Research Site

Buffalo, New York, 14263, United States
Research Site

New York, New York, 10029, United States
Research Site

Chapel Hill, North Carolina, 27599, United States
Research Site

Columbus, Ohio, 43210, United States
Research Site

Portland, Oregon, 97239, United States
Research Site

Philadelphia, Pennsylvania, 19107, United States
Research Site

Houston, Texas, 77030, United States
Research Site

Charlottesville, Virginia, 22908, United States
Research Site

Seattle, Washington, 98195, United States
Research Site

Milwaukee, Wisconsin, 53215, United States
Research Site

Milwaukee, Wisconsin, 53226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.